Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (671-680 of 755) with videos related to

Pageof 76
Sort By:
Arthritis and Rheumatism|December 30, 2006
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192Christopher P Denton, Peter A Merkel, Daniel E Furst, et al.
Blood|August 15, 2002
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomesPeter A McSweeney, Richard A Nash, Keith M Sullivan, et al.
Arthritis and Rheumatism|July 13, 2002
Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritisTino Munster, John P Gibbs, Danny Shen, et al.
Annals of the Rheumatic Diseases|September 1, 2010
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trialMarco Matucci-Cerinic, Christopher P Denton, Daniel E Furst, et al.
Arthritis and Rheumatism|October 2, 2002
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenonPeter A Merkel, Karen Herlyn, Richard W Martin, et al.
Annals of the Rheumatic Diseases|March 31, 2012
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011D E Furst, E C Keystone, J Braun, et al.
The Journal of Rheumatology|April 3, 2008
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)Christian E Antoni, Arthur Kavanaugh, Désirée van der Heijde, et al.
Clinical and Experimental Rheumatology|August 6, 2016
Examination of the association of sex and race/ethnicity with appearance concerns: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort studyLisa R Jewett, Linda Kwakkenbos, Marie-Eve Carrier, et al.
Annals of the Rheumatic Diseases|June 8, 2010
Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAITAllen D Sawitzke, Helen Shi, Martha F Finco, et al.
Annals of the Rheumatic Diseases|February 23, 2011
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010D E Furst, E C Keystone, J Braun, et al.
Pageof 76

Showing results (671-680 of 755) with videos related to

Sort By:
Pageof 76
Arthritis and Rheumatism|December 30, 2006
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192Christopher P Denton, Peter A Merkel, Daniel E Furst, et al.
Blood|August 15, 2002
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomesPeter A McSweeney, Richard A Nash, Keith M Sullivan, et al.
Arthritis and Rheumatism|July 13, 2002
Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritisTino Munster, John P Gibbs, Danny Shen, et al.
Annals of the Rheumatic Diseases|September 1, 2010
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trialMarco Matucci-Cerinic, Christopher P Denton, Daniel E Furst, et al.
Arthritis and Rheumatism|October 2, 2002
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenonPeter A Merkel, Karen Herlyn, Richard W Martin, et al.
Annals of the Rheumatic Diseases|March 31, 2012
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011D E Furst, E C Keystone, J Braun, et al.
The Journal of Rheumatology|April 3, 2008
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)Christian E Antoni, Arthur Kavanaugh, Désirée van der Heijde, et al.
Clinical and Experimental Rheumatology|August 6, 2016
Examination of the association of sex and race/ethnicity with appearance concerns: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort studyLisa R Jewett, Linda Kwakkenbos, Marie-Eve Carrier, et al.
Annals of the Rheumatic Diseases|June 8, 2010
Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAITAllen D Sawitzke, Helen Shi, Martha F Finco, et al.
Annals of the Rheumatic Diseases|February 23, 2011
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010D E Furst, E C Keystone, J Braun, et al.
Pageof 76